
Jim Cramer says J&J is a 'metaphor for what's working' in the stock market
CNBC
CNBC
Johnson & Johnson is a prime example of the kind of stock doing well in the broader market as investors shy away from the volatile artificial intelligence trade. "[J & J] is a metaphor for what's working," Jim Cramer said Monday on CNBC, as shares of the pharma and medtech giant hit another all-time high before reversing lower in a terrible market. Investors have been rotating into defensive sectors, such as healthcare and consumer staples, as stocks tied to the AI boom have fallen on hard times. It's an evolving dynamic Jim has been capitalizing on in recent weeks as the Club has been trimming data center exposure and diversifying into defensives. It was a big part of our Annual Meeting earlier this month. Over the past month, healthcare and consumer staples are the market's two top performers, with gains of 7% and 6%, respectively, crushing the S & P 500 's nearly 3% decline. Tech, over the same stretch, is down more than 9%, due to concerns about what the Democratic wave in the midterm elections might mean for the data center buildout. The fallout from the leadership scandal at Nvidia has added to the uncertainty. "J & J is the exact opposite of Nvidia. It's a clean company. Everybody loves J & J," Jim added. We initiated a position in Johnson & Johnson in early April. The stock is up 20% since then, logging a record-high close Friday. Shares opened higher Monday after the company announced it's buying clinical-stage biopharmaceutical company Ollin Biosciences for $2.2 billion up front and another up to $1.13 billion if certain milestones are met. This deal will expand J & J's treatments for serious eye diseases. JNJ YTD mountain Johnson & Johnson YTD Jim has been bullish on J & J for quite some time, noting the company's strong pipeline of drugs. This includes its leading blood cancer treatments and newer products, like Icotyde , its one-of-a-kind oral solution for plaque psoriasis. Plus, J & J managed to mitigate a major legal headwind stemming from its talc products that weighed on the company for years. Beyond that, Jim pointed to J & J's strong fundamentals and management's ability to execute well. Last month, J & J delivered better-than-expected revenue and earnings for the third quarter. The stock, however, dropped nearly 6%, due to disappointing performance in the MedTech segment and the tendency for shares to trade poorly on earnings day. Jim argued that investors sometimes overlook the company's underlying results immediately following quarterly releases, only to recognize its strength later. As we wrote in our Q3 earnings analysis , "A big reason why we're comfortable looking past the weakness in MedTech is that there's so much to like on the pharmaceutical side." The company is taking steps to boost MedTech growth potential, with a planned spin-off of its orthopedics business by 2027. Next month, J & J is set to report its fourth-quarter results. (Jim Cramer's Charitable Trust is long JNJ. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
AI Summary
Johnson & Johnson shares hit an all-time high as investors rotate into defensive sectors like healthcare and consumer staples, which gained 7% and 6% over the past month while tech fell more than 9%. Jim Cramer called J&J a metaphor for what's working, citing its strong pipeline, Q3 earnings beat, and $2.2 billion Ollin Biosciences acquisition.
Sentiment analysis
AI insights
low
16h ago
general
Financial analysis
Relevance
medium
Market sensitivity
medium
Affected sectors
Affected assets
Follow this story on TV
Live charts and AI commentary on one screen with Trade on tv.